ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

Standard of care practice in Adjuvant HR+ Breast Cancer before ASCO 2023 #oncology #ASCO2023 #cancerПодробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-FontecedroПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

ASCO 2023: Dr. Hatem SolimanПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

ASCO 2023 Expert Report on novelties in the treatment of colorectal cancer by S. StintzingПодробнее

What to look forward to in breast cancer at ASCO 2023Подробнее

New and emerging agents in HER2-negative metastatic breast cancer: Implications for practiceПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

BRCA Mutations in HER2-Negative Breast CancerПодробнее

Top breast cancer abstracts at ASCO 2023: NATALEE and PHERGainПодробнее

Breast Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Stephanie GraffПодробнее

What prognosis for ER Negative PR Positive and HER2 Negative Breast Cancer Survivor | Onco PowerПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее